Jim Neal


Mr. Neal, who currently serves as chief executive officer and board member for XOMA Corporation (NASD: XOMA), has nearly 35 years of life science industry leadership experience.  His expertise spans such areas as development and commercialization of novel technologies and products, as well as formation and oversight of successful global business and technology collaborations.  In his current role at XOMA, Mr. Neal spearheaded and secured the requisite capital to support a strategic transition of the company’s operations to focus on a royalty monetization model.  He also served as the vice president of business development and chief operating officer of XOMA from 2009-2016 until his appointment as CEO.  Prior to XOMA, Mr. Neal served as acting chief executive officer of Entelos, Inc, a leader in bio-simulation technologies, at which he was responsible for partnerships with global pharmaceutical companies such as Eli Lilly and GlaxoSmithKline.  He was chief executive officer at Iconix Biosciences at the time it was acquired by Entelos in 2007.  While at Iconix, Mr. Neal was credited with establishing multi-year collaborations with Bristol-Myers Squibb, Abbott Labs, Eli Lilly and the U.S. Food and Drug Administration.  He also previously served as executive vice president of Incyte Genomics, where he led the global commercial activities with pharmaceutical company collaborators and partners including Pfizer, Aventis and Schering-Plough, as well as sales, marketing and business development activities for the company.

Mr. Neal earned his bachelor’s degree in biology and his master’s degree in genetics and plant breeding from the University of Manitoba, Canada, and holds an executive MBA degree from Washington University in St. Louis, Missouri.